|
MedChemExpress
chk inhibitors ![]() Chk Inhibitors, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/prexasertib/Prexasertib/pmc08994821-628-0-5 Average 94 stars, based on 1 article reviews
chk inhibitors - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
TargetMol
prexasertib dihydrochloride ![]() Prexasertib Dihydrochloride, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/prexasertib/Prexasertib+dihydrochloride/pmc12718461-64-0-3 Average 93 stars, based on 1 article reviews
prexasertib dihydrochloride - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
MedChemExpress
ly2606368 ![]() Ly2606368, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/prexasertib/Prexasertib/pmc07408003-197-12-13 Average 94 stars, based on 1 article reviews
ly2606368 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
MedChemExpress
prexasertib ![]() Prexasertib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/prexasertib/Prexasertib+dihydrochloride/pmc10769073-97-10-11 Average 93 stars, based on 1 article reviews
prexasertib - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Selleck Chemicals
prexasertib hcl ![]() Prexasertib Hcl, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/prexasertib/Prexasertib+HCl/pm38400057-36-13-18 Average 95 stars, based on 1 article reviews
prexasertib hcl - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Eli Lilly
prexasertib ![]() Prexasertib, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/prexasertib/prexasertib/pm34304248-53-5-12 Average 90 stars, based on 1 article reviews
prexasertib - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Prexa Pharmaceuticals Inc
prexasertib prexa ![]() Prexasertib Prexa, supplied by Prexa Pharmaceuticals Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/prexasertib/prexasertib+prexa/pmc09006609-207-32-33 Average 90 stars, based on 1 article reviews
prexasertib prexa - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Prexa Pharmaceuticals Inc
prexasertib ![]() Prexasertib, supplied by Prexa Pharmaceuticals Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/prexasertib/prexasertib/10__1158_slash_1535___7163__mct___16___0352-185-32-33 Average 90 stars, based on 1 article reviews
prexasertib - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Kudos Pharmaceuticals
chk1 inhibitor prexasertib ![]() Chk1 Inhibitor Prexasertib, supplied by Kudos Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/prexasertib/chk1+inhibitor+prexasertib/pmc10931009-246-9-18 Average 90 stars, based on 1 article reviews
chk1 inhibitor prexasertib - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Eli Lilly
prexasertib monolactate monohydrate ![]() Prexasertib Monolactate Monohydrate, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/prexasertib/prexasertib+monolactate+monohydrate/10__1002_slash_anie__201710482-56-18-5 Average 90 stars, based on 1 article reviews
prexasertib monolactate monohydrate - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Eli Lilly
5-({5-[2-(3-aminopropoxy-1,1,3,3- d 4 )-6-methoxyphenyl]-1h-pyrozol-3-yl}amino)pyrazine-2-carbonitrile hydrochloride [prexasertib- d 4 , internal standard (istd)] ![]() 5 ({5 [2 (3 Aminopropoxy 1,1,3,3 D 4 ) 6 Methoxyphenyl] 1h Pyrozol 3 Yl}Amino)pyrazine 2 Carbonitrile Hydrochloride [Prexasertib D 4 , Internal Standard (Istd)], supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/prexasertib/5+++5++2++3+aminopropoxy+1+1+3+3++d+4+++6+methoxyphenyl++1h+pyrozol+3+yl+amino+pyrazine+2+carbonitrile+hydrochloride++prexasertib++d+4+++internal+standard++istd++/pmc05984718-56-14-27 Average 90 stars, based on 1 article reviews
5-({5-[2-(3-aminopropoxy-1,1,3,3- d 4 )-6-methoxyphenyl]-1h-pyrozol-3-yl}amino)pyrazine-2-carbonitrile hydrochloride [prexasertib- d 4 , internal standard (istd)] - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Cambridge Bioscience
prexasertib ![]() Prexasertib, supplied by Cambridge Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/prexasertib/prexasertib/pm36103534-226-33-39 Average 90 stars, based on 1 article reviews
prexasertib - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Science translational medicine
Article Title: Small molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma
doi: 10.1126/scitranslmed.aba7401
Figure Lengend Snippet: (A) Dose-response analyses of the indicated CHK1/2 or CHK1 inhibitors in D283 (red) and D425 (blue) cells. The ED50 is indicated. Mean ± SEM were calculated from 3–4 independent experiments. (B) Results from assays to determine the interactions between the four CHK inhibitors shown and three MB chemotherapies: 4-HPC, CDDP, and GEM. The mean combination index (CI, horizontal bar) was determined from the indicated pairwise drug combinations using D283 and D425 cells, with 3–5 independent experiments performed. Result for each experiment is indicated by the symbols. Table provides the summary of data shown in B (mean CI ± SD). Synergistic interactions are in green; additive interactions are indicated in black.
Article Snippet:
Techniques:
Journal: STAR Protocols
Article Title: Protocol for high-content drug screening using tumor organoids on a 384-pillar plate platform
doi: 10.1016/j.xpro.2025.104250
Figure Lengend Snippet:
Article Snippet:
Techniques: Recombinant, Membrane, Software, Imaging
Journal: PLOS ONE
Article Title: HTSplotter: An end-to-end data processing, analysis and visualisation tool for chemical and genetic in vitro perturbation screening
doi: 10.1371/journal.pone.0296322
Figure Lengend Snippet: A) Dose-response curve of BAY1895334, in which the Emax is 70.37% of confluency, the relative (rel.) IC50 is 101.15 nM and the absolute (abs.) IC50 could not be determined. B) Dose-response curve of prexasertib, in which the Emax is 56.53% of confluency, the rel. IC50 is 8.45 nM and the abs. IC50 could not be determined. C) Dose-response curve of MK-1775, in which the Emax is 17.80% of confluency, the rel. IC50 is 1072.60 nM and the abs. IC50 is 1276.81 nM. D) GR dose-response curve of BAY1895334, in which the GR Emax is 0.74, the GR rel. 50 is 86.32 nM and the GR abs. 50 could not be determined. E) GR dose-response curve of prexasertib, in which the GR Emax is 0.61, the GR rel. 50 is 8.20 nM and the GR abs. 50 could not be determined. F) GR dose-response curve of MK-1775, in which the GR Emax is 0.02, the GR rel. 50 is 1221.05 nM and the GR abs. 50 is 1336.03 nM.
Article Snippet: The drugs used were: AZD2281 (Selleckchem, S1060), MK-1775 (Selleckchem, S1525),
Techniques:
Journal: PLOS ONE
Article Title: HTSplotter: An end-to-end data processing, analysis and visualisation tool for chemical and genetic in vitro perturbation screening
doi: 10.1371/journal.pone.0296322
Figure Lengend Snippet: A) Dose-effect combination heatmap over time of a combination range of MK-1775 with a range of prexasertib (7 X 7 matrix). B) Dose-effect combination heatmap over time of a combination range of MK-1775 with range of BAY1895344 (7 X 7 matrix).
Article Snippet: The drugs used were: AZD2281 (Selleckchem, S1060), MK-1775 (Selleckchem, S1525),
Techniques:
Journal: PLOS ONE
Article Title: HTSplotter: An end-to-end data processing, analysis and visualisation tool for chemical and genetic in vitro perturbation screening
doi: 10.1371/journal.pone.0296322
Figure Lengend Snippet: XY- plot and growth rate plot of the best dose-effect combination of MK-1775 with BAY1895344 (A, B) or MK-1775 with Prexasertib (C, D). Relative confluence is the confluence relative to the control. The dash line indicates the predicted combination effect, computed according to the BI method, Eq . The growth rate is computed according to Eq . The grey dash line on the growth rate plot indicates the stop on the growth rate. A) Relative confluence inhibition over time of BAY1895344 at 166.8 nM combined with MK-1775 at 137.2 nM. The BI scores at 24h, 48h and 72h are 0.28, 0.39 and 0.42, respectively. B) Growth rate of each condition in relation to the control. BAY1895344 growth rates at 24h, 48h and 72h, are 0.86 h -1 , 0.74 h -1 and 0.74 h -1 respectively. MK-1775 growth rates at 24h, 48h and 72h, are 1.10 h -1 , 1.02 h -1 and 1.01 h -1 respectively. The combined condition growth rates at 24h, 48h and 72h are 0.28 h -1 , 0.18 h -1 and 0.14 h -1 . C) Relative confluence inhibition plot over time of prexasertib at 4.7 nM combined with MK-1775 at 137.2 nM. The BI scores at 24h, 48h and 72h are 0.25 h -1 , 0.47 h -1 and 0.56 h -1 , respectively. D) In relation to the control. Prexasertib growth rates at 24h, 48h and 72h, are 1.00 h -1 , 0.96 h -1 and 0.96 h -1 respectively. MK-1775 growth rates at 24h, 48h and 72h, are 1.10 h -1 , 1.02 h -1 and 1.01 h -1 respectively. The combined condition growth rates at 24h, 48h and 72h are 0.37 h -1 , 0.26 h -1 , 0.29 h -1 .
Article Snippet: The drugs used were: AZD2281 (Selleckchem, S1060), MK-1775 (Selleckchem, S1525),
Techniques: Control, Inhibition
Journal: PLOS ONE
Article Title: HTSplotter: An end-to-end data processing, analysis and visualisation tool for chemical and genetic in vitro perturbation screening
doi: 10.1371/journal.pone.0296322
Figure Lengend Snippet: A) HTSplotter heatmap over time and at final time point (72h) of dose-effect combination of prexasertib with MK-1775, maximum BI score of 0.56 at 72h. B) SynergyFinder Plus heatmap of dose-effect combination of prexasertib with MK-1775, with BI score of 17.29, p-value = 1.62x10 -07 . C) SynergyFinder Plus heatmap of dose-effect combination of BAY1895344 with MK-1775, with BI score of 4.51, with a p-value = 3.35x10 -03 . D) HTSplotter heatmap over time and at final time point (72h) of dose-effect combination of BAY1895344 with MK-1775, maximum BI score of 0.42 at 72h. HTSplotter has a fixed legend scale from -1 to 1.
Article Snippet: The drugs used were: AZD2281 (Selleckchem, S1060), MK-1775 (Selleckchem, S1525),
Techniques:
Journal: Viruses
Article Title: Transcriptional Differential Analysis of Nitazoxanide-Mediated Anticanine Parvovirus Effect in F81 Cells.
doi: 10.3390/v16020282
Figure Lengend Snippet: Figure 6. Inhibition of CPV in F81 cells by cell cycle checkpoint kinase 1 (Chk1) inhibitors and their effects on the expression of G2/M phase transition-related genes. (A) Western blot was used to detect the effects of the NTZ (S1627, 2.5 µM and 5 µM), S2735 (MK-8776, 2 µM and 4 µM) and S7178 (Prexasertib HCl, 10 nM and 20 nM) treatments on CPV replication. “DMSO” represents the control group treated with 0.1% DMSO. (B) The statistical graph obtained from the calculation of the intensity bands in experiment A. “D” represents the control group treated with 0.1% DMSO. (C–G) qRT-PCR was used to detect the effects of the NTZ (S1627, 2.5 µM and 5 µM), S2735 (MK-8776, 2 µM and 4 µM) and S7178 (Prexasertib HCl, 10 nM and 20 nM) treatments on the expression of the CDC25B (C), CDC25C (D), CDC20 (E), CCNA2 (F) and CCNB1 (G) genes associated with G2/M phase transition. “D” represents the control group treated with 0.1% DMSO. The β-actin gene was used as an internal control. The relative fold changes in each gene expression were calculated using the comparative 2−∆∆CT method; * p < 0.05, ** p < 0.01, *** p < 0.005 and **** p < 0.001 were considered statistically significant.
Article Snippet: Nitazoxanide (NTZ) and the cell cycle checkpoint kinase 1 (Chk1) inhibitors MK-8776 and
Techniques: Inhibition, Expressing, Sublimation, Western Blot, Control, Quantitative RT-PCR, Gene Expression
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells
doi: 10.1186/s13046-022-02360-y
Figure Lengend Snippet: Impact of clinically relevant CHK1 inhibitors in inducing ERα degradation and preventing proliferation in MCF-7 and Y537S cells. A Sensitivity scores of ERα-negative (black) and ERα-positive (red) breast cancer cell lines to AZD7762 (AZD), prexasertib (Prexa), MK8776 (MK), PF-477736 (PF), Ly-2603618 (Ly), PD-407824 (PD), CHIR-124 (CHIR), and SB-218078 (SB). A’ Sensitivity scores of ERα-negative (black) and ERα-positive (red) breast cancer cell lines to 4OH-Tamoxifen (Tam), VE822 (VE), and KU60019 (KU). * ( p < 0.05), ** ( p < 0.01) and **** ( p < 0.001) indicate significant differences to drugs among ERα-negative or ERα-positive breast cancer cell lines. The graphs have been generated by downloading the experimental data from the Broad Institute through the DepMap portal https://depmap.org/portal . Each dot of the plot in ( A and A’ ) represents the value of the indicated parameter in a single breast cancer cell line. Crude data are given in supplementary table . Western blot ( B ) and relative densitometric analyses ( B’ ) of ERα expression levels in MCF-7 (yellow) and Y537S (red) cells treated for 24 h with the indicated doses of prexasertib (Prexa). The loading control was done by evaluating vinculin expression in the same filter. Significant differences with respect to control (0) were obtained by unpaired two-tailed Student’s t-test. Data show the mean ± the standard deviations, **** p < 0.0001. The number of replicates is given as solid dots in the bar graph. C Growth curve analyses in MCF-7 (yellow) and Y537S (red) cells were performed as indicated in the material and method section for 5 days with different doses of prexasertib (Prexa). The graph shows only one concentration for each cell line and the normalized cell index ( i.e., cell number), which is detected with the xCelligence DP device and calculated at each time point with respect to the control sample. Each sample was measured in a quadruplicate. For details, please see the material and methods section. D The inhibitor concentration 50 (IC 50 ) was calculated for each cell line at 5 days after initial treatment
Article Snippet: Western blot ( B ) and relative densitometric analyses ( B’ ) of ERα expression levels in MCF-7 (yellow) and Y537S (red) cells treated for 24 h with the indicated doses of
Techniques: Generated, Western Blot, Expressing, Control, Two Tailed Test, Concentration Assay
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells
doi: 10.1186/s13046-022-02360-y
Figure Lengend Snippet: Evaluation of the inhibitor-dependent mechanism for ERα degradation. A In vitro ERα competitive binding assays for MK8776 (MK), CCT241533 (CCT), VE822 (VE), KU60019 (KU), AZD7762 (AZD) prexasertib (Prexa), GDC-0575 (GDC), and 17β-estradiol (E2) were performed at different doses of the compounds and using a florescent E2 as the tracer. Relative inhibitor concentration 50 (IC 50 , i.e., K d ) is given in the graph. The experiment was performed twice in quintuplicate. Western blot ( B - C ) and relative densitometric analysis ( D ) of ERα levels in MCF-7 ( B ) and Y537S ( C ) cells pre-treated with cycloheximide (CHX) at the indicated doses for 6 h and then treated with AZD7762 at the indicated dose for 24 h. The loading control was done by evaluating vinculin expression in the same filter. The number of replicates is given as solid dots in the bar graph. Significant differences with respect to CTR sample are calculated by Student t-test and indicated by **** ( p -value < 0.0001). Significant differences with respect to the CHX sample are calculated by Student t-test and indicated by ° ( p -value < 0.05), and °°°° ( p -value < 0.0001)
Article Snippet: Western blot ( B ) and relative densitometric analyses ( B’ ) of ERα expression levels in MCF-7 (yellow) and Y537S (red) cells treated for 24 h with the indicated doses of
Techniques: In Vitro, Binding Assay, Concentration Assay, Western Blot, Control, Expressing
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells
doi: 10.1186/s13046-022-02360-y
Figure Lengend Snippet: CHK1 inhibitors synergic effects with 4OH-Tamoxifen in MCF-7 cells. Kaplan–Meier plots showing the relapse-free survival (RFS) probability in women carrying breast tumors expressing either ERα, progesterone receptor (PR) but not HER2 ( A ) or ERα, but not PR or both expressing or not HER2 ( B ) as a function of CHK1 mRNA levels. All possible cutoff values between the lower and upper quartiles are automatically computed ( i.e., auto select best cutoff on the website), and the best performing threshold is used as a cutoff . Details of the parameters of the curves are given in supplementary table . Significant differences between the RFS are given as p -value in each panel. Synergy map of 12 days-treated MCF-7 ( C ) and T47D-1 ( D ) cells with different doses of 4OH-Tamoxifen (Tam) and AZD7762 (AZD) or prexasertib (Prexa) ( C , and D left and right panels, respectively). Growth curves in MCF-7 ( C’ ) or T47D-1 ( D’ ) cells show the synergic effect of each combination of compounds with selected doses. Significant differences with respect to untreated ( i.e., -,-) samples are calculated by Student t-test and indicated by **** p -value < 0.0001. Significant differences between Tam + AZD with respect to Tam alone or AZD alone are calculated by Student t-test and indicated by ° p -value < 0.05. Significant differences between Tam + Prexa with respect to Tam alone or Prexa alone are calculated by Student t-test and indicated by ^ p -value < 0.05. For details, please see the material and methods section
Article Snippet: Western blot ( B ) and relative densitometric analyses ( B’ ) of ERα expression levels in MCF-7 (yellow) and Y537S (red) cells treated for 24 h with the indicated doses of
Techniques: Expressing
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells
doi: 10.1186/s13046-022-02360-y
Figure Lengend Snippet: CHK1 inhibitors synergic effects with palbociclib and abemaciclib in Y537S cells. A Kaplan–Meier plots showing the relapse-free survival (RFS) probability in women carrying breast tumors expressing ERα, PR, or both expressing or not HER2 as a function of CHK1 mRNA levels. All possible cutoff values between the lower and upper quartiles are automatically computed ( i.e., auto select best cutoff on the website), and the best performing threshold is used as a cutoff . Details of the parameters of the curves are given in supplementary table . Significant differences between the RFS are given as p-value in each panel. B mRNA expression levels of CHK1 and CHK2 in patient-derived xenograft (PDX) immortalized cell lines stratified as indicated in the graph. Data have been extracted by the supplementary materials given in . Volcano plot showing the mRNA expression as a function of the p -value of the indicated proteins ( i.e., presenilin2 -pS2, TFF—red, CHK1 – blue) in CRISPR/CAS9 engineered MCF-7 cells expressing the Y537S ( C ) or the D538G ( D ) ERα mutant as extracted by the supplementary materials given in . Synergy map of 5 days-treated Y537S cells with different doses of MK8776 (MK) ( E ) or prexasertib (Prexa) and palbociclib (Palbo) or abemaciclib (Abe) ( E and F left and right panels, respectively). Significant differences with respect to untreated ( i.e., -,-) samples are calculated by Student t-test and indicated by **** p -value < 0.0001. Significant differences between MK + Abe with respect to MK alone or Abe alone are calculated by Student t-test and indicated by °°°° p -value < 0.0001. Significant differences between MK + Palbo with respect to MK alone or Palbo alone are calculated by Student t-test and indicated by ^^^^ p -value < 0.0001. Significant differences between Prexa + Abe with respect to Prexa alone or Abe alone are calculated by Student t-test and indicated by °°°° p -value < 0.0001. Significant differences between Prexa + Palbo with respect to Prexa alone or Palbo alone are calculated by Student t-test and indicated by ^^^^ p -value < 0.0001. Growth curves in Y537S cells showing the synergic effect of each combination of compounds with selected doses are shown in ( E’ and F’ ). For details, please see the material and methods section
Article Snippet: Western blot ( B ) and relative densitometric analyses ( B’ ) of ERα expression levels in MCF-7 (yellow) and Y537S (red) cells treated for 24 h with the indicated doses of
Techniques: Expressing, Derivative Assay, CRISPR, Mutagenesis
Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells
doi: 10.1186/s13046-022-02360-y
Figure Lengend Snippet: Effect of CHK1 inhibitors in 3D-models of breast cancer. Images ( A , B ) and quantitation ( A’ , B’ ) of tumor spheroids surface area ( A , A’ ) and alginate-based cultures ( B , B’ ) generated in MCF-7 and Y537S cells, treated at time 0 with CHK1 inhibitors ( i.e., AZD7762, AZD—1 μM; prexasertib, Prexa—1 μM; MK8776—MK 5 μM) or left untreated (CTR), for 7 days. The number of replicates is given as solid dots in the graphs. Significant differences with respect to the CTR sample were determined by unpaired two-tailed Student’s t-test: **** p -value < 0.0001; *** p -value < 0.001. Scale bars equal to 200 µm for panel A and 50.0 mm for panel B
Article Snippet: Western blot ( B ) and relative densitometric analyses ( B’ ) of ERα expression levels in MCF-7 (yellow) and Y537S (red) cells treated for 24 h with the indicated doses of
Techniques: Quantitation Assay, Generated, Two Tailed Test
Journal: Cancers
Article Title: Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future Possibilities
doi: 10.3390/cancers16050963
Figure Lengend Snippet: CHK1 kinase signaling, and inhibition involved in SCLC immunotherapy. ( A , B ) CHK1, a DNA-repair protein, is overexpressed in SCLC. It participates in the DNA repair process. The combination of the CHK1 inhibitor SRA737 and a low dose of gemcitabine (chemotherapeutic drug) augments the impact of PD-L1 IC blockade (via the use of anti-PD-L1 antibody). This augmentation is achieved by significantly elevating the presence of CD8 + T cells, DCs, and M1 macrophages within the TME. [Created with BioRender.com (accessed on 18 February 2024)].
Article Snippet: To achieve the intended objective, the use of the
Techniques: Inhibition
Journal: Cancers
Article Title: Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future Possibilities
doi: 10.3390/cancers16050963
Figure Lengend Snippet: A list of ICI clinical trials with their protein kinase (PK) inhibitors for SCLC.
Article Snippet: To achieve the intended objective, the use of the
Techniques: Clinical Proteomics, Activation Assay, Expressing, In Vivo, Inhibition